Eli Lilly and Co. received approval from the FDA for Strattera for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.     The safety and efficacy of Strattera in the maintenance of ADHD was demonstrated in an 18-month trial of about 600 pateints aged six to 15 years, who met DSM-IV (Diagnostic an...